Alvotech Disclosed The Resubmission To The U.S. Food And Drug Administration Of Biologics License Applications For Avt05, A Proposed Biosimilar To Simponi And Simponi Aria (Golimumab), And Avt06, A Proposed Biosimilar To Eylea (Aflibercept) 2 Mg